Dr. Uwe Buecheler has more than 30 years experience in the biopharmaceutical industry. He is Senior Advisor in Biopharmaceuticals to the Board of Managing Directors at Boehringer Ingelheim, and Senior Vice President of the Biopharma Business Unit at Boehringer Ingelheim. He has held a variety of senior roles, including across regulatory affairs, CMC/GMP development, biosafety, quality, and as site head. He led an expansion of Boehringer Ingelheim’s Global Operations Network in the US and China, pioneered 1st Biologics MAH approval in Shanghai, and has led/contributed to major expansion projects in aseptic processing, microbial manufacturing and large-scale mammalian cell culture operations. Throughout his career, he has overseen more than 30 biologics launches, including more than five Top-20 global biopharmaceuticals.
Uwe Buecheler joined Boehringer Ingelheim in 1991. For several years he led the quality unit, as well as process science for biopharmaceuticals. In 2006, he was appointed site head for the Boehringer Ingelheim site in Biberach, Germany, and was a member of the board of the German subsidiary responsible for the mammalian cell culture business at the Biberach site. In October 2010, he was responsible for global biopharmaceuticals operations, including sites in Germany, Austria and US. Since May 2014, he has been responsible for the entire biopharma business unit as Senior Vice President.
Uwe Buecheler has a PhD in Molecular Biology from the University of Heidelberg and the Cancer research Center in Heidelberg. Prior to joining Boehringer Ingelheim he also worked at Roche (former Boehringer Mannheim site in Penzberg). He was awarded Professor h.c. at the University of Ulm, and is member of Advisory boards of University´s and the Society for Biochemistry and Molecular Biology (GBM). He is Chairman of the Biopharma Cluster South Germany and is Member of several (Bio-) Pharmaceutical Industry Associations including the international leadership forum of ISPE.